P59.22 Biomarker Testing for Advanced Lung Cancer by Next-Generation Sequencing in Real World Practice

2021 ◽  
Vol 16 (10) ◽  
pp. S1157
Author(s):  
J.N. Minatta ◽  
Y. Ferreira ◽  
A. Antivero ◽  
J. Pandolfi ◽  
H. Garcia Rivello ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Real World ◽  
Advanced Lung Cancer ◽  
Next Generation ◽  
Biomarker Testing ◽  
Generation Sequencing

Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 6563-6563 ◽  
Author(s):  
Carolyn Jean Presley ◽  
Pamela R. Soulos ◽  
Anne C. Chiang ◽  
Janina A Longtine ◽  
Kerin B. Adelson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Advanced Lung Cancer ◽  
Next Generation ◽  
Small Cell Lung ◽  
Biomarker Testing ◽  
Generation Sequencing

6563 Background: The use of next generation sequencing (NGS) in patients with advanced non-small cell lung cancer (NSCLC) is increasing. This study explored disparities in the use of NGS testing. Methods: This retrospective observational study utilized Flatiron Health’s longitudinal, demographically and geographically diverse database containing electronic health record data from 191 oncology practices across the U.S. We identified patients diagnosed with advanced (stages IIIB/IV or recurrent) non-squamous NSCLC who received first line treatment and either NGS testing or standard biomarker testing (e.g., EGFR, ALK) alone. NGS included any multi-gene panel testing > 30 genes. Logistic regression modeled the association between patient characteristics and receipt of NGS testing, accounting for clustering of patients by oncology practice. Results: Among 5,688 adults with advanced NSCLC, 4,813 (84.6%) patients received standard biomarker testing alone and 875 (15.4%) patients received NGS testing. The median age of the sample was 67y (IQR: 41-85), the majority was white (63.6%) vs. black (7.5%) vs. unknown (13.4%), and had a history of smoking (79.9%). Among the youngest patients ( < 45y), 31.5% received NGS compared to 11.3% among the oldest (76-85y; P < .001). Approximately 16% of white patients received testing, compared to 11.4% of black patients (P < .001). Patients with Medicaid received testing less often than commercially insured patients (11.7% vs 17.0%; P = .10). Patients had significantly lower odds of receiving NGS testing if they were older (≥75 vs. < 45 years of age; adjusted OR: 0.21, 95% CI: 0.13-0.34), black vs. white race (aOR: 0.63, 95% CI: 0.44-0.90) or were Medicaid vs. commercially insured (aOR: 0.54, 95% CI: 0.30-0.97). Conclusions: Significant age, race, and insurance-related disparities exist in the receipt of NGS testing among patients with advanced lung cancer in real world clinical practice.

P24.12 Biomarker Testing for Advanced Lung Cancer by Next-Generation Sequencing in Elderly Patients

2021 ◽  
Vol 16 (10) ◽  
pp. S1035
Author(s):  
L. Basbus ◽  
J.N. Minatta ◽  
Y. Ferreira ◽  
A. Antivero ◽  
J. Pandolfi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Elderly Patients ◽  
Advanced Lung Cancer ◽  
Next Generation ◽  
Biomarker Testing ◽  
Generation Sequencing

Survival following implementation of next-generation sequencing in routine diagnostics of advanced lung cancer: Results of the German Network Genomic Medicine.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 9085-9085 ◽  
Author(s):  
Anna Kostenko ◽  
Sebastian Yves Friedrich Michels ◽  
Jana Fassunke ◽  
Matthias Scheffler ◽  
Sabine Merkelbach-Bruse ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Genomic Medicine ◽  
Advanced Lung Cancer ◽  
Next Generation ◽  
Routine Diagnostics ◽  
Generation Sequencing
Sign in / Sign up

Export Citation Format

Share Document